| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| United States Department of Veterans Affairs | 14 | 2022 | 126 | 1.610 |
Why?
|
| Delivery of Health Care | 8 | 2022 | 444 | 1.430 |
Why?
|
| Quality of Health Care | 13 | 2022 | 347 | 1.340 |
Why?
|
| Health Services Research | 8 | 2021 | 264 | 1.310 |
Why?
|
| Translational Medical Research | 7 | 2020 | 39 | 1.280 |
Why?
|
| Evidence-Based Practice | 6 | 2022 | 56 | 1.250 |
Why?
|
| Papillomavirus Infections | 3 | 2024 | 136 | 1.130 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2024 | 127 | 1.130 |
Why?
|
| Humans | 93 | 2024 | 18430 | 1.110 |
Why?
|
| Practice Patterns, Physicians' | 12 | 2020 | 350 | 1.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 8 | 2024 | 392 | 1.030 |
Why?
|
| Quality Improvement | 6 | 2017 | 207 | 0.990 |
Why?
|
| Periodicals as Topic | 3 | 2020 | 14 | 0.970 |
Why?
|
| Diffusion of Innovation | 5 | 2017 | 44 | 0.960 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2022 | 180 | 0.930 |
Why?
|
| Kidney Transplantation | 2 | 2022 | 29 | 0.900 |
Why?
|
| Editorial Policies | 2 | 2012 | 5 | 0.810 |
Why?
|
| Patient Education as Topic | 6 | 2020 | 214 | 0.790 |
Why?
|
| Hospitals, Veterans | 3 | 2014 | 34 | 0.790 |
Why?
|
| United States | 34 | 2022 | 4164 | 0.760 |
Why?
|
| Information Dissemination | 7 | 2020 | 57 | 0.750 |
Why?
|
| Parkinson Disease | 4 | 2022 | 15 | 0.700 |
Why?
|
| Continuity of Patient Care | 6 | 2020 | 112 | 0.680 |
Why?
|
| Attitude of Health Personnel | 7 | 2020 | 226 | 0.570 |
Why?
|
| Capacity Building | 2 | 2015 | 11 | 0.560 |
Why?
|
| Smoking Cessation | 3 | 2008 | 199 | 0.540 |
Why?
|
| Evidence-Based Medicine | 9 | 2018 | 195 | 0.530 |
Why?
|
| Mental Health Services | 3 | 2020 | 161 | 0.530 |
Why?
|
| Ischemic Attack, Transient | 3 | 2021 | 28 | 0.510 |
Why?
|
| Community Health Services | 5 | 2022 | 86 | 0.510 |
Why?
|
| Risk Reduction Behavior | 5 | 2021 | 114 | 0.510 |
Why?
|
| Female | 44 | 2024 | 13136 | 0.510 |
Why?
|
| Primary Health Care | 9 | 2020 | 848 | 0.500 |
Why?
|
| Personnel, Hospital | 1 | 2014 | 9 | 0.500 |
Why?
|
| Chiropractic | 1 | 2014 | 12 | 0.490 |
Why?
|
| Health Promotion | 6 | 2022 | 294 | 0.480 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2022 | 342 | 0.460 |
Why?
|
| Early Detection of Cancer | 4 | 2024 | 526 | 0.450 |
Why?
|
| Biomedical Research | 2 | 2020 | 93 | 0.450 |
Why?
|
| Delivery of Health Care, Integrated | 5 | 2022 | 567 | 0.440 |
Why?
|
| Research Design | 7 | 2021 | 402 | 0.430 |
Why?
|
| Education, Medical, Graduate | 1 | 2013 | 20 | 0.430 |
Why?
|
| Schools, Medical | 1 | 2013 | 17 | 0.430 |
Why?
|
| Referral and Consultation | 4 | 2020 | 180 | 0.430 |
Why?
|
| Male | 36 | 2022 | 10440 | 0.410 |
Why?
|
| Aged | 28 | 2024 | 6417 | 0.410 |
Why?
|
| Stroke | 4 | 2021 | 311 | 0.410 |
Why?
|
| Interviews as Topic | 6 | 2020 | 327 | 0.410 |
Why?
|
| Patient-Centered Care | 4 | 2020 | 228 | 0.400 |
Why?
|
| Decision Making | 4 | 2020 | 204 | 0.400 |
Why?
|
| Guidelines as Topic | 4 | 2014 | 43 | 0.400 |
Why?
|
| Alzheimer Disease | 2 | 2002 | 43 | 0.400 |
Why?
|
| Ethics Committees, Research | 1 | 2011 | 11 | 0.380 |
Why?
|
| Research Personnel | 4 | 2020 | 30 | 0.380 |
Why?
|
| Self-Management | 2 | 2021 | 30 | 0.370 |
Why?
|
| Outcome Assessment (Health Care) | 5 | 2017 | 254 | 0.350 |
Why?
|
| Academies and Institutes | 3 | 2020 | 7 | 0.340 |
Why?
|
| Cooperative Behavior | 4 | 2020 | 102 | 0.340 |
Why?
|
| Mass Screening | 3 | 2024 | 690 | 0.340 |
Why?
|
| Middle Aged | 29 | 2024 | 8284 | 0.340 |
Why?
|
| Arthritis, Rheumatoid | 5 | 2007 | 40 | 0.330 |
Why?
|
| Patient Outcome Assessment | 2 | 2020 | 29 | 0.330 |
Why?
|
| Practice Guidelines as Topic | 8 | 2008 | 333 | 0.320 |
Why?
|
| Health Policy | 3 | 2015 | 136 | 0.310 |
Why?
|
| Electronic Health Records | 4 | 2022 | 747 | 0.310 |
Why?
|
| Transitional Care | 3 | 2017 | 20 | 0.300 |
Why?
|
| Patient Discharge | 4 | 2017 | 153 | 0.300 |
Why?
|
| Exercise Therapy | 2 | 2020 | 74 | 0.290 |
Why?
|
| Total Quality Management | 4 | 2004 | 27 | 0.290 |
Why?
|
| HIV Infections | 3 | 2020 | 695 | 0.280 |
Why?
|
| Guideline Adherence | 3 | 2007 | 162 | 0.280 |
Why?
|
| Clinical Protocols | 2 | 2017 | 45 | 0.270 |
Why?
|
| Patient Readmission | 3 | 2017 | 162 | 0.270 |
Why?
|
| Dementia | 4 | 2011 | 105 | 0.270 |
Why?
|
| Specialization | 3 | 2007 | 26 | 0.270 |
Why?
|
| California | 13 | 2024 | 2365 | 0.260 |
Why?
|
| Nervous System Diseases | 3 | 2004 | 20 | 0.260 |
Why?
|
| Ambulatory Care Facilities | 1 | 2006 | 77 | 0.260 |
Why?
|
| Surveys and Questionnaires | 11 | 2024 | 1389 | 0.260 |
Why?
|
| Severity of Illness Index | 5 | 2020 | 476 | 0.240 |
Why?
|
| Veterans | 3 | 2020 | 138 | 0.240 |
Why?
|
| Heart Failure | 2 | 2022 | 398 | 0.230 |
Why?
|
| Medicine | 2 | 2007 | 23 | 0.230 |
Why?
|
| Safety-net Providers | 3 | 2021 | 63 | 0.220 |
Why?
|
| Hypertension | 2 | 2021 | 524 | 0.220 |
Why?
|
| Cost-Benefit Analysis | 4 | 2019 | 270 | 0.220 |
Why?
|
| Curriculum | 2 | 2013 | 40 | 0.220 |
Why?
|
| Indans | 1 | 2002 | 1 | 0.210 |
Why?
|
| Piperidines | 1 | 2002 | 1 | 0.210 |
Why?
|
| Phenylcarbamates | 1 | 2002 | 1 | 0.210 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2002 | 4 | 0.210 |
Why?
|
| Outcome and Process Assessment (Health Care) | 5 | 2017 | 110 | 0.210 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2022 | 56 | 0.210 |
Why?
|
| Geriatric Assessment | 1 | 2002 | 40 | 0.210 |
Why?
|
| Quality Assurance, Health Care | 5 | 2017 | 188 | 0.200 |
Why?
|
| Laboratories | 1 | 2022 | 23 | 0.200 |
Why?
|
| Cardiovascular Diseases | 2 | 2020 | 630 | 0.200 |
Why?
|
| Preventive Health Services | 2 | 2020 | 166 | 0.200 |
Why?
|
| Comparative Effectiveness Research | 2 | 2020 | 77 | 0.200 |
Why?
|
| Medicare | 4 | 2017 | 214 | 0.200 |
Why?
|
| Hyperkalemia | 1 | 2022 | 17 | 0.200 |
Why?
|
| Information Services | 4 | 2001 | 18 | 0.200 |
Why?
|
| Hip Fractures | 1 | 2022 | 68 | 0.190 |
Why?
|
| Acute Kidney Injury | 1 | 2022 | 43 | 0.190 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2022 | 53 | 0.190 |
Why?
|
| Program Evaluation | 4 | 2018 | 244 | 0.190 |
Why?
|
| Quarantine | 1 | 2021 | 10 | 0.190 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 90 | 0.190 |
Why?
|
| Secondary Prevention | 2 | 2021 | 52 | 0.190 |
Why?
|
| Disease Management | 2 | 2015 | 143 | 0.190 |
Why?
|
| Papillomavirus Vaccines | 1 | 2022 | 118 | 0.190 |
Why?
|
| Adult | 18 | 2024 | 7910 | 0.190 |
Why?
|
| Stroke Rehabilitation | 1 | 2020 | 3 | 0.190 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 116 | 0.190 |
Why?
|
| Nurses | 1 | 2020 | 40 | 0.190 |
Why?
|
| Medication Adherence | 2 | 2021 | 267 | 0.180 |
Why?
|
| Peer Group | 1 | 2001 | 48 | 0.180 |
Why?
|
| Financing, Organized | 1 | 2020 | 5 | 0.180 |
Why?
|
| HIV Long-Term Survivors | 1 | 2020 | 2 | 0.180 |
Why?
|
| Culturally Competent Care | 1 | 2020 | 12 | 0.180 |
Why?
|
| Economics, Behavioral | 1 | 2020 | 4 | 0.180 |
Why?
|
| Organizations | 1 | 2020 | 10 | 0.180 |
Why?
|
| Quality Indicators, Health Care | 1 | 2022 | 197 | 0.180 |
Why?
|
| Social Networking | 1 | 2020 | 20 | 0.180 |
Why?
|
| Models, Organizational | 2 | 2015 | 65 | 0.170 |
Why?
|
| Women's Health | 2 | 2020 | 207 | 0.170 |
Why?
|
| Hospice and Palliative Care Nursing | 1 | 2019 | 6 | 0.170 |
Why?
|
| House Calls | 1 | 2019 | 13 | 0.170 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2020 | 59 | 0.170 |
Why?
|
| Home Care Services | 1 | 2019 | 23 | 0.170 |
Why?
|
| Antihypertensive Agents | 1 | 2021 | 172 | 0.170 |
Why?
|
| Social Support | 1 | 2001 | 214 | 0.170 |
Why?
|
| Blood Pressure | 1 | 2021 | 310 | 0.160 |
Why?
|
| Aged, 80 and over | 10 | 2019 | 2003 | 0.160 |
Why?
|
| Glomerular Filtration Rate | 1 | 2019 | 157 | 0.160 |
Why?
|
| Documentation | 3 | 2016 | 45 | 0.160 |
Why?
|
| Patient Selection | 1 | 2020 | 198 | 0.160 |
Why?
|
| Interdisciplinary Communication | 2 | 2015 | 22 | 0.160 |
Why?
|
| Anti-HIV Agents | 1 | 2020 | 154 | 0.160 |
Why?
|
| African Americans | 3 | 2021 | 490 | 0.160 |
Why?
|
| Health Care Costs | 2 | 2019 | 251 | 0.160 |
Why?
|
| Sweden | 1 | 2017 | 19 | 0.150 |
Why?
|
| Health Priorities | 2 | 2020 | 28 | 0.150 |
Why?
|
| Los Angeles | 5 | 2020 | 141 | 0.150 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 182 | 0.150 |
Why?
|
| Retrospective Studies | 7 | 2022 | 2550 | 0.150 |
Why?
|
| Rheumatology | 2 | 2007 | 8 | 0.150 |
Why?
|
| Cerebral Hemorrhage | 1 | 2017 | 14 | 0.140 |
Why?
|
| Research | 2 | 2016 | 73 | 0.140 |
Why?
|
| Patient Care Management | 2 | 2020 | 32 | 0.140 |
Why?
|
| Communication | 2 | 2015 | 202 | 0.140 |
Why?
|
| Sleep Medicine Specialty | 1 | 2016 | 5 | 0.140 |
Why?
|
| Pulmonary Medicine | 1 | 2016 | 19 | 0.140 |
Why?
|
| HLA-B27 Antigen | 1 | 2016 | 1 | 0.140 |
Why?
|
| Hemochromatosis Protein | 1 | 2016 | 8 | 0.140 |
Why?
|
| Factor V | 1 | 2016 | 5 | 0.140 |
Why?
|
| Organizational Objectives | 2 | 2014 | 19 | 0.140 |
Why?
|
| Hospitals | 1 | 2017 | 80 | 0.140 |
Why?
|
| Caregivers | 3 | 2011 | 126 | 0.130 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2015 | 27 | 0.130 |
Why?
|
| Critical Care | 1 | 2016 | 73 | 0.130 |
Why?
|
| Genetic Testing | 1 | 2016 | 89 | 0.130 |
Why?
|
| Awards and Prizes | 1 | 2015 | 10 | 0.130 |
Why?
|
| Hospital Administration | 1 | 2015 | 3 | 0.130 |
Why?
|
| Treatment Outcome | 5 | 2021 | 1296 | 0.130 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 146 | 0.130 |
Why?
|
| Program Development | 1 | 2015 | 81 | 0.130 |
Why?
|
| Medical History Taking | 2 | 2013 | 37 | 0.130 |
Why?
|
| Health Education | 2 | 2012 | 115 | 0.130 |
Why?
|
| Pilot Projects | 3 | 2020 | 237 | 0.120 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2024 | 407 | 0.120 |
Why?
|
| Walking | 1 | 2015 | 87 | 0.120 |
Why?
|
| Healthcare Disparities | 1 | 2017 | 211 | 0.120 |
Why?
|
| Sexual Partners | 1 | 2014 | 37 | 0.120 |
Why?
|
| Capitation Fee | 4 | 2000 | 12 | 0.120 |
Why?
|
| Single-Blind Method | 3 | 2021 | 47 | 0.120 |
Why?
|
| General Practice | 1 | 2014 | 6 | 0.120 |
Why?
|
| United States Agency for Healthcare Research and Quality | 2 | 1994 | 14 | 0.120 |
Why?
|
| Benchmarking | 3 | 2004 | 45 | 0.110 |
Why?
|
| Hereditary Breast and Ovarian Cancer Syndrome | 1 | 2013 | 1 | 0.110 |
Why?
|
| Genetic Services | 1 | 2013 | 2 | 0.110 |
Why?
|
| Self Care | 3 | 2020 | 175 | 0.110 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2013 | 16 | 0.110 |
Why?
|
| Missouri | 1 | 2013 | 9 | 0.110 |
Why?
|
| Health Status | 4 | 2020 | 328 | 0.110 |
Why?
|
| Neoplasms | 2 | 2012 | 457 | 0.110 |
Why?
|
| Journal Impact Factor | 1 | 2012 | 2 | 0.110 |
Why?
|
| Time Factors | 3 | 2020 | 1136 | 0.100 |
Why?
|
| Risk Factors | 4 | 2022 | 3449 | 0.100 |
Why?
|
| Emergency Service, Hospital | 1 | 2015 | 382 | 0.100 |
Why?
|
| Pneumonia | 2 | 2003 | 56 | 0.100 |
Why?
|
| Cross-Sectional Studies | 7 | 2008 | 1360 | 0.100 |
Why?
|
| Patient Care Team | 3 | 2021 | 127 | 0.100 |
Why?
|
| Health Maintenance Organizations | 4 | 1997 | 479 | 0.100 |
Why?
|
| Public Health | 1 | 2012 | 82 | 0.100 |
Why?
|
| Informed Consent | 1 | 2011 | 20 | 0.100 |
Why?
|
| Physicians | 3 | 2021 | 141 | 0.100 |
Why?
|
| Neurology | 2 | 2004 | 6 | 0.090 |
Why?
|
| Antirheumatic Agents | 2 | 2007 | 13 | 0.090 |
Why?
|
| Health Care Surveys | 3 | 2006 | 247 | 0.090 |
Why?
|
| Uterine Diseases | 2 | 2000 | 5 | 0.090 |
Why?
|
| Education, Medical, Continuing | 3 | 2020 | 31 | 0.090 |
Why?
|
| Disease Progression | 2 | 2019 | 271 | 0.090 |
Why?
|
| Societies, Medical | 3 | 2016 | 74 | 0.090 |
Why?
|
| Hysterectomy | 2 | 2000 | 30 | 0.090 |
Why?
|
| Minority Groups | 2 | 2022 | 105 | 0.080 |
Why?
|
| Joints | 2 | 2007 | 3 | 0.080 |
Why?
|
| Self-Examination | 2 | 2007 | 4 | 0.080 |
Why?
|
| Models, Theoretical | 1 | 2008 | 76 | 0.080 |
Why?
|
| Breast Neoplasms | 1 | 2016 | 1037 | 0.080 |
Why?
|
| Utilization Review | 2 | 2000 | 56 | 0.080 |
Why?
|
| Multicenter Studies as Topic | 2 | 2020 | 91 | 0.080 |
Why?
|
| Inservice Training | 2 | 2020 | 15 | 0.070 |
Why?
|
| Memory Disorders | 1 | 2007 | 7 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 1269 | 0.070 |
Why?
|
| Vaccination | 2 | 2022 | 674 | 0.070 |
Why?
|
| Asian Americans | 2 | 2021 | 182 | 0.070 |
Why?
|
| Personal Health Services | 1 | 2007 | 4 | 0.070 |
Why?
|
| Community-Acquired Infections | 2 | 2003 | 24 | 0.070 |
Why?
|
| Reimbursement Mechanisms | 2 | 2004 | 20 | 0.070 |
Why?
|
| Child | 3 | 2022 | 2571 | 0.070 |
Why?
|
| Health Plan Implementation | 1 | 2006 | 41 | 0.070 |
Why?
|
| Hispanic Americans | 2 | 2021 | 428 | 0.070 |
Why?
|
| Algorithms | 2 | 2004 | 241 | 0.060 |
Why?
|
| Focus Groups | 2 | 2016 | 154 | 0.060 |
Why?
|
| Health Personnel | 1 | 2006 | 126 | 0.060 |
Why?
|
| Papanicolaou Test | 1 | 2024 | 38 | 0.060 |
Why?
|
| Vaginal Smears | 1 | 2024 | 50 | 0.060 |
Why?
|
| Papillomaviridae | 1 | 2024 | 53 | 0.060 |
Why?
|
| Perception | 1 | 2024 | 59 | 0.060 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2004 | 7 | 0.060 |
Why?
|
| Comorbidity | 2 | 2007 | 619 | 0.060 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2004 | 22 | 0.060 |
Why?
|
| Malpractice | 1 | 2004 | 11 | 0.060 |
Why?
|
| Length of Stay | 3 | 2016 | 183 | 0.060 |
Why?
|
| Quality of Life | 2 | 2015 | 529 | 0.060 |
Why?
|
| Professional-Patient Relations | 2 | 2001 | 48 | 0.060 |
Why?
|
| Cohort Studies | 4 | 2016 | 2672 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 2 | 2003 | 142 | 0.060 |
Why?
|
| Residence Characteristics | 2 | 2016 | 256 | 0.050 |
Why?
|
| Pressure Ulcer | 1 | 2003 | 5 | 0.050 |
Why?
|
| Homes for the Aged | 1 | 2003 | 6 | 0.050 |
Why?
|
| Nursing Homes | 1 | 2003 | 10 | 0.050 |
Why?
|
| Endometriosis | 1 | 2002 | 4 | 0.050 |
Why?
|
| Pelvic Pain | 1 | 2002 | 5 | 0.050 |
Why?
|
| Rivastigmine | 1 | 2002 | 1 | 0.050 |
Why?
|
| Lorazepam | 1 | 2002 | 4 | 0.050 |
Why?
|
| Risperidone | 1 | 2002 | 4 | 0.050 |
Why?
|
| Carbamates | 1 | 2002 | 7 | 0.050 |
Why?
|
| Chi-Square Distribution | 1 | 2002 | 160 | 0.050 |
Why?
|
| Advance Directives | 1 | 2002 | 6 | 0.050 |
Why?
|
| Mood Disorders | 1 | 2002 | 19 | 0.050 |
Why?
|
| Logistic Models | 2 | 2002 | 962 | 0.050 |
Why?
|
| Neuropsychological Tests | 1 | 2002 | 38 | 0.050 |
Why?
|
| Cholic Acids | 1 | 2022 | 1 | 0.050 |
Why?
|
| Family Practice | 1 | 2002 | 53 | 0.050 |
Why?
|
| Nurse's Role | 1 | 2022 | 8 | 0.050 |
Why?
|
| Activities of Daily Living | 1 | 2002 | 96 | 0.050 |
Why?
|
| Social Class | 1 | 2022 | 125 | 0.050 |
Why?
|
| Cats | 1 | 2021 | 8 | 0.050 |
Why?
|
| Cognition | 1 | 2002 | 82 | 0.050 |
Why?
|
| Fluoxetine | 1 | 2021 | 26 | 0.050 |
Why?
|
| Medical Records | 3 | 2007 | 106 | 0.050 |
Why?
|
| Physician Assistants | 1 | 2021 | 7 | 0.050 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2021 | 9 | 0.050 |
Why?
|
| Psychology, Social | 1 | 2001 | 3 | 0.050 |
Why?
|
| Community Health Workers | 1 | 2021 | 15 | 0.050 |
Why?
|
| Prejudice | 1 | 2001 | 24 | 0.050 |
Why?
|
| Nurse Practitioners | 1 | 2021 | 20 | 0.050 |
Why?
|
| Interprofessional Relations | 1 | 2001 | 25 | 0.050 |
Why?
|
| Psychiatry | 1 | 2001 | 23 | 0.050 |
Why?
|
| Psychotherapy | 1 | 2021 | 59 | 0.050 |
Why?
|
| Nursing Evaluation Research | 1 | 2020 | 3 | 0.050 |
Why?
|
| Animals | 1 | 2021 | 261 | 0.050 |
Why?
|
| Organizational Policy | 2 | 2016 | 17 | 0.050 |
Why?
|
| C-Reactive Protein | 1 | 2021 | 58 | 0.050 |
Why?
|
| Anxiety Disorders | 1 | 2021 | 93 | 0.050 |
Why?
|
| Government Programs | 1 | 2020 | 11 | 0.050 |
Why?
|
| Bibliometrics | 1 | 2020 | 3 | 0.040 |
Why?
|
| Job Satisfaction | 1 | 2000 | 20 | 0.040 |
Why?
|
| Multimorbidity | 1 | 2020 | 14 | 0.040 |
Why?
|
| Chronic Disease | 3 | 2016 | 468 | 0.040 |
Why?
|
| Pandemics | 1 | 2022 | 292 | 0.040 |
Why?
|
| Protective Factors | 1 | 2020 | 33 | 0.040 |
Why?
|
| Unnecessary Procedures | 1 | 2000 | 26 | 0.040 |
Why?
|
| Gynecology | 1 | 2000 | 23 | 0.040 |
Why?
|
| Incidence | 2 | 2019 | 1314 | 0.040 |
Why?
|
| Education, Medical | 2 | 1996 | 15 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2020 | 69 | 0.040 |
Why?
|
| Feeding Behavior | 1 | 2020 | 168 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 232 | 0.040 |
Why?
|
| Viral Load | 1 | 2020 | 135 | 0.040 |
Why?
|
| Multivariate Analysis | 3 | 2011 | 598 | 0.040 |
Why?
|
| Reproducibility of Results | 3 | 2007 | 399 | 0.040 |
Why?
|
| Self Report | 1 | 2021 | 256 | 0.040 |
Why?
|
| Oregon | 1 | 2019 | 222 | 0.040 |
Why?
|
| Depressive Disorder | 1 | 2001 | 231 | 0.040 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 157 | 0.040 |
Why?
|
| Stress, Psychological | 1 | 2020 | 147 | 0.040 |
Why?
|
| Washington | 1 | 2019 | 388 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2016 | 1314 | 0.040 |
Why?
|
| European Continental Ancestry Group | 1 | 2021 | 554 | 0.040 |
Why?
|
| Rorschach Test | 1 | 1978 | 1 | 0.040 |
Why?
|
| Reimbursement, Incentive | 2 | 2012 | 31 | 0.040 |
Why?
|
| Age Factors | 2 | 2015 | 965 | 0.040 |
Why?
|
| Stakeholder Participation | 1 | 2018 | 23 | 0.040 |
Why?
|
| Reminder Systems | 2 | 2013 | 94 | 0.040 |
Why?
|
| Data Collection | 2 | 2015 | 275 | 0.040 |
Why?
|
| Sex Factors | 2 | 2015 | 661 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 724 | 0.040 |
Why?
|
| Group Practice, Prepaid | 1 | 1997 | 9 | 0.040 |
Why?
|
| Independent Practice Associations | 1 | 1997 | 8 | 0.040 |
Why?
|
| Cataract Extraction | 1 | 1997 | 3 | 0.040 |
Why?
|
| Fee-for-Service Plans | 1 | 1997 | 28 | 0.040 |
Why?
|
| Oncologists | 1 | 2016 | 7 | 0.040 |
Why?
|
| Clinical Medicine | 1 | 1996 | 5 | 0.040 |
Why?
|
| Culture | 1 | 2016 | 29 | 0.040 |
Why?
|
| Point-of-Care Systems | 1 | 2016 | 9 | 0.030 |
Why?
|
| Monitoring, Ambulatory | 1 | 2016 | 18 | 0.030 |
Why?
|
| Lung Diseases | 1 | 2016 | 43 | 0.030 |
Why?
|
| Sleep Wake Disorders | 1 | 2016 | 38 | 0.030 |
Why?
|
| Exercise | 1 | 2021 | 495 | 0.030 |
Why?
|
| Practice Management, Medical | 1 | 1995 | 17 | 0.030 |
Why?
|
| Group Practice | 1 | 1995 | 26 | 0.030 |
Why?
|
| Medication Reconciliation | 1 | 2015 | 5 | 0.030 |
Why?
|
| Senior Centers | 1 | 2015 | 2 | 0.030 |
Why?
|
| Korea | 1 | 2015 | 9 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2016 | 337 | 0.030 |
Why?
|
| Waiting Lists | 1 | 2015 | 12 | 0.030 |
Why?
|
| Anxiety | 1 | 2016 | 156 | 0.030 |
Why?
|
| Adolescent | 2 | 2021 | 3798 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2020 | 1143 | 0.030 |
Why?
|
| China | 1 | 2015 | 130 | 0.030 |
Why?
|
| Decision Making, Computer-Assisted | 1 | 1995 | 7 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 1996 | 95 | 0.030 |
Why?
|
| Self Efficacy | 1 | 2015 | 71 | 0.030 |
Why?
|
| Software | 1 | 1995 | 21 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2016 | 271 | 0.030 |
Why?
|
| Mental Disorders | 1 | 1978 | 295 | 0.030 |
Why?
|
| Safe Sex | 1 | 2014 | 4 | 0.030 |
Why?
|
| Condoms | 1 | 2014 | 32 | 0.030 |
Why?
|
| Continental Population Groups | 1 | 2016 | 315 | 0.030 |
Why?
|
| Young Adult | 1 | 2021 | 2518 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2015 | 197 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2014 | 65 | 0.030 |
Why?
|
| Managed Care Programs | 1 | 1995 | 347 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2004 | 321 | 0.030 |
Why?
|
| Family Health | 1 | 2013 | 49 | 0.030 |
Why?
|
| Social Conformity | 1 | 1992 | 1 | 0.030 |
Why?
|
| District of Columbia | 1 | 1992 | 17 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2014 | 272 | 0.030 |
Why?
|
| Ethnic Groups | 1 | 2016 | 501 | 0.030 |
Why?
|
| Interpersonal Relations | 1 | 2011 | 42 | 0.020 |
Why?
|
| Hospitalization | 1 | 2017 | 847 | 0.020 |
Why?
|
| Linear Models | 2 | 2003 | 243 | 0.020 |
Why?
|
| Motivation | 2 | 2004 | 137 | 0.020 |
Why?
|
| Regression Analysis | 2 | 2002 | 319 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2007 | 47 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2006 | 71 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2006 | 72 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2008 | 673 | 0.020 |
Why?
|
| Colorectal Neoplasms | 1 | 2012 | 656 | 0.020 |
Why?
|
| Range of Motion, Articular | 1 | 2004 | 2 | 0.020 |
Why?
|
| Defensive Medicine | 1 | 2004 | 3 | 0.010 |
Why?
|
| Pennsylvania | 1 | 2003 | 27 | 0.010 |
Why?
|
| Virginia | 1 | 2003 | 5 | 0.010 |
Why?
|
| Organizational Culture | 1 | 2003 | 18 | 0.010 |
Why?
|
| Drug Utilization | 1 | 2003 | 134 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2004 | 365 | 0.010 |
Why?
|
| Patient Participation | 1 | 2004 | 144 | 0.010 |
Why?
|
| Expert Testimony | 1 | 2002 | 4 | 0.010 |
Why?
|
| Mass Media | 1 | 2002 | 17 | 0.010 |
Why?
|
| Feedback | 1 | 2002 | 22 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2004 | 701 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2001 | 86 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2001 | 167 | 0.010 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2001 | 10 | 0.010 |
Why?
|
| Gender Identity | 1 | 2001 | 36 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 2001 | 51 | 0.010 |
Why?
|
| Random Allocation | 1 | 2000 | 41 | 0.010 |
Why?
|
| Sexual Behavior | 1 | 2001 | 123 | 0.010 |
Why?
|
| Social Desirability | 1 | 1978 | 1 | 0.010 |
Why?
|
| MMPI | 1 | 1978 | 2 | 0.010 |
Why?
|
| Schizophrenia | 1 | 1978 | 79 | 0.010 |
Why?
|
| Physicians, Family | 1 | 1997 | 47 | 0.010 |
Why?
|
| Likelihood Functions | 1 | 1997 | 48 | 0.010 |
Why?
|
| Sex Distribution | 1 | 1997 | 198 | 0.010 |
Why?
|
| Physician Executives | 1 | 1996 | 4 | 0.010 |
Why?
|
| Quality Control | 1 | 1996 | 48 | 0.010 |
Why?
|
| Age Distribution | 1 | 1997 | 261 | 0.010 |
Why?
|
| Preventive Medicine | 1 | 1996 | 25 | 0.010 |
Why?
|
| Neurologic Examination | 1 | 1996 | 3 | 0.010 |
Why?
|
| Decision Trees | 1 | 1996 | 20 | 0.010 |
Why?
|
| Insurance, Health | 1 | 1997 | 217 | 0.010 |
Why?
|
| Models, Statistical | 1 | 1996 | 185 | 0.010 |
Why?
|
| Computer-Assisted Instruction | 1 | 1995 | 11 | 0.010 |
Why?
|
| User-Computer Interface | 1 | 1995 | 28 | 0.010 |
Why?
|
| Terminology as Topic | 1 | 1994 | 21 | 0.010 |
Why?
|
| Depression | 1 | 1978 | 518 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 1997 | 530 | 0.010 |
Why?
|